Consort Med Plc ADR (CSRMY) 14.7000 $CSRMY Cont
Post# of 273257
Posted On: 10/11/2015 7:08:05 AM
Consort Med Plc ADR (CSRMY) 14.7000 $CSRMY
Contract Research Organization Market - Global Deals and Operational Strategies
M2 - Thu Oct 08, 3:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xpsnr/contract_research) has announced the addition of the "Contract Research Organization Market - Global Deals and Operational Strategies" report to their offering. This report discusses the deals that took place in the CRO space between 2010 and April 2015, giving a thorough analysis of the major deals, operational and service strategies, and financials of key players. This report discusses the deal making activity during the past five years and in-depth analysis of the key deals involving more than 40 public and privately held CROs. The operational strategies adopted by key players in the recent years have been listed. A heatmap analysis of the key companies was done based on their firm utilization and capital management. SWOT analysis and profiles are given for the key companies in the market. Recent years have seen pharmaceutical companies struggling to balance R&D expenditure and profitability due to the rising costs of drug development and clinical trials, along with rigorous regulatory and quality assurance requirements. In a bid to boost profit margins, companies are outsourcing R&D and clinical trial activities to Contract Research Organizations (CRO) to achieve far more at a far lower cost. Scope - Overview of key reasons behind outsourcing, outsourcing service models - Examples of operational strategies - Global deals analysis by type and value - Major acquisitions and partnerships - Regional analysis of North America, Europe, Asia-Pacific and Emerging markets - Company benchmarking based on heatmap analysis - Vendor positioning - SWOT analysis and profiles of key players Key Reasons to Purchase - Identify the top players in the CRO market, financial revenues and key services offered - Analyze the key geographies that are lucrative markets for deal making, market-entry and market expansion strategies - Analyze the trends in acquisitions, licensing and other type of deals and explore potential investment opportunities - Understand the operational strategies of key players Key Topics Covered: 1. Executive Summary 2. Introduction 2.1 Market Dynamics 2.2 Operating Models 2.3 Examples of Operational Strategies 3. Global Deal Analysis 3.1 Collaborations and Acquisitions 3.2 Major Acquisitions 3.3 Major Partnerships 4. Regional Analysis 4.1 North America 4.2 Europe 4.3 Asia-Pacific 5. Emerging Markets 5.1 Market Assessment 5.2 Acquisitions 5.3 Firm Utilization 5.4 Firm Utilization and Capital Management 5.5 Company Benchmarking 5.6 Vendor Positioning 6. Profiles and SWOT Analysis 7. Appendix Companies Mentioned - Almac Group - Assign - Aurigon - Avillion - BioPharma - CMIC Holdings - Carlina - Catalent - Celonic and PharmaLex - Charles River - Chiltern International - Consort Medical - Covance - Cromos Pharma - EPS Corporation - Euprotech - Eurofins Scientific - Hangzhou Tigermed - Harlan Labs - ICON - Laboratory Corporation of America Holdings - MPI Research - Meiji Seika - Noble Life Sciences - Novotech - PRA Health - Parexel - Pfizer - Protagen - Quintiles - Recipharm - Sanofi - Simbec Research - Sun Pharma - WuXi PharmaTech For more information visit http://www.researchandmarkets.com/research/3x...t_research
LH: 112.35 (+0.64), WX: 44.15 (+0.04)
Injectable Drug Delivery Market: By Devices, Therapeutics & Formulations 2015 - 2020
M2 - Wed Sep 30, 8:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ltfg29/injectable_drug) has announced the addition of the "Injectable Drug Delivery Market:By Devices, Therapeutics & Formulations (2015 - 2020)" report to their offering. The global injectable drug delivery devices market is expected to increase from around $ 11.6 bn in 2013 to around $ 17.5 bn in 2018. Self-injection devices are expected to grow at the highest growth rate of 16.1% with conventional injection devices growing at only 7.4% during the forecast period 2013 - 2018. The Global Injectable Drug Delivery Devices Market has been analyzed with respect to the demand for devices from different countries across the globe. These markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2020. The drug injection devices market has been segmented into conventional injectors and self-injection devices broadly. Similarly the drug formulations market has been segmented into the conventional drugs and novel drugs segments. The therapeutic areas are further segmented and analyzed in this report. While conventional devices are growing at a CAGR of 7.37%, self-injection devices are expected to grow at 16.6% during 2013 - 2018. Conventional injection devices hold around 87% market share currently but this is expected to decrease to around 83% by 2018, as the use of self-injection devices increases in the next 5 years. Analyzing the competitive landscape of the global conventional injectable devices market for 2012 the report puts forward the opinion that Becton Dickinson & Co. had the top position with a market share of around 27% followed by Baxter International Inc with a share of 23%. Overall these two companies along with Terumo Corporation and Schott AG together held market share of around 85%. Key Topics Covered: 1. Market Overview 2. Executive Summary 3. Market Landscape 4. Global Injectable Drug Delivery - Market Forces 5. Global Injectable Drug Delivery Market - Strategic Analysis 6. Global Injectable Drug Delivery Market - By Type 7. Global Injectable Drug Delivery Market - By Type of Diseases 8. Global Injectable Drug Delivery Market - Geographic Analysis 9. Market Entropy 10. Company Profiles 11. Appendix Companies Mentioned - Becton Dickinson and Company (BD) - Baxter International Inc. - Consort Medical PLC - Crossject SA - Eli Lilly and Company - Elcam Medical - Novo Nordisk - Owen Mumford Ltd - Sanofi - Schott AG - Terumo Corporation - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/lt...table_drug
BDX: 137.76 (+0.64), NVO: 54.61 (-0.12), BAX: 33.21 (-0.04), LLY: 86.14 (+2.37)
Atlas Genetics Completes $20m Series C Fundraising
PR Newswire - Thu Jan 29, 1:00AM CST
Atlas Genetics Ltd ("Atlas" or the "Company"
, the ultra-rapid "test and treat" molecular diagnostics company, today announces the completion of a Series C financing, raising $20 million from a syndicate including existing investors and one new investor, RMI Partners.
JNJ: 95.37 (+0.29), NVS: 91.90 (-0.71)
Contract Research Organization Market - Global Deals and Operational Strategies
M2 - Thu Oct 08, 3:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3xpsnr/contract_research) has announced the addition of the "Contract Research Organization Market - Global Deals and Operational Strategies" report to their offering. This report discusses the deals that took place in the CRO space between 2010 and April 2015, giving a thorough analysis of the major deals, operational and service strategies, and financials of key players. This report discusses the deal making activity during the past five years and in-depth analysis of the key deals involving more than 40 public and privately held CROs. The operational strategies adopted by key players in the recent years have been listed. A heatmap analysis of the key companies was done based on their firm utilization and capital management. SWOT analysis and profiles are given for the key companies in the market. Recent years have seen pharmaceutical companies struggling to balance R&D expenditure and profitability due to the rising costs of drug development and clinical trials, along with rigorous regulatory and quality assurance requirements. In a bid to boost profit margins, companies are outsourcing R&D and clinical trial activities to Contract Research Organizations (CRO) to achieve far more at a far lower cost. Scope - Overview of key reasons behind outsourcing, outsourcing service models - Examples of operational strategies - Global deals analysis by type and value - Major acquisitions and partnerships - Regional analysis of North America, Europe, Asia-Pacific and Emerging markets - Company benchmarking based on heatmap analysis - Vendor positioning - SWOT analysis and profiles of key players Key Reasons to Purchase - Identify the top players in the CRO market, financial revenues and key services offered - Analyze the key geographies that are lucrative markets for deal making, market-entry and market expansion strategies - Analyze the trends in acquisitions, licensing and other type of deals and explore potential investment opportunities - Understand the operational strategies of key players Key Topics Covered: 1. Executive Summary 2. Introduction 2.1 Market Dynamics 2.2 Operating Models 2.3 Examples of Operational Strategies 3. Global Deal Analysis 3.1 Collaborations and Acquisitions 3.2 Major Acquisitions 3.3 Major Partnerships 4. Regional Analysis 4.1 North America 4.2 Europe 4.3 Asia-Pacific 5. Emerging Markets 5.1 Market Assessment 5.2 Acquisitions 5.3 Firm Utilization 5.4 Firm Utilization and Capital Management 5.5 Company Benchmarking 5.6 Vendor Positioning 6. Profiles and SWOT Analysis 7. Appendix Companies Mentioned - Almac Group - Assign - Aurigon - Avillion - BioPharma - CMIC Holdings - Carlina - Catalent - Celonic and PharmaLex - Charles River - Chiltern International - Consort Medical - Covance - Cromos Pharma - EPS Corporation - Euprotech - Eurofins Scientific - Hangzhou Tigermed - Harlan Labs - ICON - Laboratory Corporation of America Holdings - MPI Research - Meiji Seika - Noble Life Sciences - Novotech - PRA Health - Parexel - Pfizer - Protagen - Quintiles - Recipharm - Sanofi - Simbec Research - Sun Pharma - WuXi PharmaTech For more information visit http://www.researchandmarkets.com/research/3x...t_research
LH: 112.35 (+0.64), WX: 44.15 (+0.04)
Injectable Drug Delivery Market: By Devices, Therapeutics & Formulations 2015 - 2020
M2 - Wed Sep 30, 8:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ltfg29/injectable_drug) has announced the addition of the "Injectable Drug Delivery Market:By Devices, Therapeutics & Formulations (2015 - 2020)" report to their offering. The global injectable drug delivery devices market is expected to increase from around $ 11.6 bn in 2013 to around $ 17.5 bn in 2018. Self-injection devices are expected to grow at the highest growth rate of 16.1% with conventional injection devices growing at only 7.4% during the forecast period 2013 - 2018. The Global Injectable Drug Delivery Devices Market has been analyzed with respect to the demand for devices from different countries across the globe. These markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2020. The drug injection devices market has been segmented into conventional injectors and self-injection devices broadly. Similarly the drug formulations market has been segmented into the conventional drugs and novel drugs segments. The therapeutic areas are further segmented and analyzed in this report. While conventional devices are growing at a CAGR of 7.37%, self-injection devices are expected to grow at 16.6% during 2013 - 2018. Conventional injection devices hold around 87% market share currently but this is expected to decrease to around 83% by 2018, as the use of self-injection devices increases in the next 5 years. Analyzing the competitive landscape of the global conventional injectable devices market for 2012 the report puts forward the opinion that Becton Dickinson & Co. had the top position with a market share of around 27% followed by Baxter International Inc with a share of 23%. Overall these two companies along with Terumo Corporation and Schott AG together held market share of around 85%. Key Topics Covered: 1. Market Overview 2. Executive Summary 3. Market Landscape 4. Global Injectable Drug Delivery - Market Forces 5. Global Injectable Drug Delivery Market - Strategic Analysis 6. Global Injectable Drug Delivery Market - By Type 7. Global Injectable Drug Delivery Market - By Type of Diseases 8. Global Injectable Drug Delivery Market - Geographic Analysis 9. Market Entropy 10. Company Profiles 11. Appendix Companies Mentioned - Becton Dickinson and Company (BD) - Baxter International Inc. - Consort Medical PLC - Crossject SA - Eli Lilly and Company - Elcam Medical - Novo Nordisk - Owen Mumford Ltd - Sanofi - Schott AG - Terumo Corporation - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/lt...table_drug
BDX: 137.76 (+0.64), NVO: 54.61 (-0.12), BAX: 33.21 (-0.04), LLY: 86.14 (+2.37)
Atlas Genetics Completes $20m Series C Fundraising
PR Newswire - Thu Jan 29, 1:00AM CST
Atlas Genetics Ltd ("Atlas" or the "Company"
, the ultra-rapid "test and treat" molecular diagnostics company, today announces the completion of a Series C financing, raising $20 million from a syndicate including existing investors and one new investor, RMI Partners. JNJ: 95.37 (+0.29), NVS: 91.90 (-0.71)
(0)
(0)Scroll down for more posts ▼